sameAs
deLIVER: Direct Acting Antiviral Effects on the LiverSofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV InfectionA Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsSurveillance and Treatment of Prisoners With Hepatitis CReal-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected PatientsPharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal ImpairmentEfficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment StudyComparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV InfectionSafety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus InfectionComparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV InfectionSofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV InfectionSofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B CirrhosisSafety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionA Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C EradicationThe Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsSimplified Antiviral Treatment Strategy for Hepatitis C in MyanmarSwitch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on MethadoneA TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgramsExpanding the Pool in Lung TransplantationSafety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenEffect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl EstradiolEfficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 CoinfectionSafety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionSafety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionA Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug UseEfficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life ConditionsSafety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV InfectionSafety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV InfectionEfficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCVReviewing DAA Efficacy Managing Patient Treatment In Online NeighbourhoodsSafety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment StudyLung Transplant HCV, Pilot StudyThe Kentucky Viral Hepatitis Treatment StudyGeneric VEL/SOF With or Without RBV for HIV/HCV Coinfected PatientsTrial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/VelpatasvirHepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative RecipientsExpanding the Pool in Orthotopic Heart TransplantationSofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C InfectionTransplanting Hepatitis C Positive Thoracic Organs
P4844
Sofosbuvir/velpatasvir: A promising combinationRibavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus.Sofosbuvir and Velpatasvir for Patients with HCV Infection.Sofosbuvir and Velpatasvir for Patients with HCV Infection.Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patientsIdentification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification
P921
Q63807808-961F9688-0702-4D9D-B327-35E1EC713548Q64151024-0DD48B33-25D5-4958-8704-B4BC71A5EF85Q64187215-76776073-2324-42F8-9679-959CC53F3565Q64223198-17291BB1-944F-40E0-AC2D-7346E83571A1Q64336178-4247F934-C065-4622-8ED9-5C2C6F4D8E38Q64351792-EBA3E2F3-2044-4FEA-8764-272953EE1477Q64599258-0F92932F-32EA-4E01-AACD-B94ABB472D3EQ64604333-B8021501-6695-4D0C-A1A8-D013893B7DCCQ64608088-D39795A1-C155-46B1-9AFA-B75786DB04CEQ64620966-9B985614-A23C-494C-8DE0-AA3FE4310C6FQ64620967-25360328-6E77-4273-ACDF-BF229EC5892AQ64620970-98BEA1BE-063C-41E2-A984-BC9152E00E87Q64622286-03729F2B-59D1-450F-95F0-7859D68E47C8Q64625356-64F08190-677B-4ED6-B2AB-75B10B45D719Q64793715-09654E0C-0418-4ADD-8767-4E5AB0D8ED9DQ64794177-BBC1646D-E508-4116-805F-9FB48680098CQ64795196-CAFF3D0C-B9D3-48A5-BDF4-60B65A754D54Q64796409-119E8AAB-3F67-48D7-ADCD-94025F1B3BC0Q64802446-45F9F3E9-F0FA-4470-AA0D-DD10F60C9E67Q64806399-196E2C8F-255D-4AE5-9A8B-FB1E647204A1Q65333180-1928BE99-0DC2-4F58-A050-0930C032D44AQ65334818-3F22C5C8-4F98-4129-BE31-F44AB9D7E919Q65344317-6CC3ACD4-0AFE-4A67-84B9-DDD0C9B6C4B8Q65346591-6F6B6AED-6DD1-4BF4-B101-E23C521B7218Q65346596-3FB089CA-2261-47B7-B8BE-D93AE92303B5Q65350175-D2EBA0D1-5AC3-435E-BDEA-6EE2DC34BC46Q65350662-02CA5A37-8894-4E7E-AAAD-B56CF85EC26AQ65367031-C06CAA42-3074-4F7D-8B39-4D9F91ED542AQ65372300-1BB3901F-117A-4722-95C7-C8CE86FFD758Q65403693-433F8D43-1C08-44C9-8466-61E645F838AAQ65466241-E66E769A-5580-4D9D-A515-891149CC9647Q66045816-4A0470B9-08AA-4C10-AA35-581B9DB750F6Q66046860-DE86D733-225E-479B-A793-BF03D2E869CCQ66066551-38CC233D-A128-4C8E-A524-DC3A4D4BC5B3Q66068099-D6ABA2D8-C2E8-413F-95BD-A2B43DEF3F0CQ66068220-03D4B315-4C2E-4E06-87BB-89B4E5AD4A02Q66068355-D970AEE4-5B5F-4D65-8FDC-2F04DAC3DAEFQ66069342-C91718E9-15F0-4AF0-9ADE-6671D58CD0BEQ66072076-C8942375-903D-44A0-B378-9C73BC7A6937Q66072209-804682E4-347E-4ABD-8CE1-8F90E31BA4CE
P4844
Q27468954-4648B464-A9F2-445F-B26E-C31AD34F5940Q39574126-906095CA-A03C-4F25-B498-1DA44320E582Q39937600-E3584CD1-14CD-403A-8CE0-BB91E8855694Q40590354-B9467D0E-508C-4F3E-A208-04983C98EE6AQ40590361-3A239283-8E32-48D5-8345-991210D872F3Q40653397-44D5ECE7-474B-4D66-A4EE-60F6545B5A1AQ40675418-86A8F815-5B43-4224-92F6-A897467D5966Q40677674-B06F44B6-1C53-4A83-8B24-609E8163B9EDQ40832971-11957BE9-1BC0-43C1-AF7A-6716B4CA5DE4Q40907444-3457A417-F37B-4888-A66A-CB0109A71BFFQ40908880-D5378A61-B91B-4406-8C38-63477BD88A8FQ40908899-9ECB75F8-BE0D-46D5-87A3-771A58D90AECQ40917225-1893D320-848D-42F2-BDB8-1D16ADE9584DQ40917300-03A6570D-AC88-4C81-B911-52D494DC54C6Q40929413-95B2124F-1D0E-4A1C-8AE1-2BA9118EA281Q41104253-1DE2E669-7067-428B-831E-27DADAD0A1F2Q42991306-A7845223-D303-41E7-93D3-2B89682C98ADQ43024346-73502A23-6B3C-4206-9321-3C7FB820C88EQ64067280-62C7111F-05E9-4004-A153-8A564A916308Q64114424-0CC8DDB4-5E07-41BE-8F4A-6F32CD78E6A1
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Velpatasviiri
@fi
Velpatasvir
@en
Velpatasvir
@es
Velpatasvir
@fr
Velpatasvir
@vi
Βελπατασβίρη
@el
Велпатасвир
@ru
فلباتاسفير
@ar
維帕他韋
@zh-hant
维帕他韦
@zh
type
label
Velpatasviiri
@fi
Velpatasvir
@en
Velpatasvir
@es
Velpatasvir
@fr
Velpatasvir
@vi
Βελπατασβίρη
@el
Велпатасвир
@ru
فلباتاسفير
@ar
維帕他韋
@zh-hant
维帕他韦
@zh
altLabel
velpatasvir
@en
prefLabel
Velpatasviiri
@fi
Velpatasvir
@en
Velpatasvir
@es
Velpatasvir
@fr
Velpatasvir
@vi
Βελπατασβίρη
@el
Велпатасвир
@ru
فلباتاسفير
@ar
維帕他韋
@zh-hant
维帕他韦
@zh
P486
P592
P6366
P661
P662
P683
P117
P2017
C[C@H]1CC[C@H](N1C(=O)[C@H](C( ...... C@@H](C9=CC=CC=C9)NC(=O)OC)COC
P2067
P2115
N0000192572
P231
1377049-84-7
P233
CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC ...... (=O)C(C9=CC=CC=C9)NC(=O)OC)COC
P234
1S/C49H54N8O8/c1-26(2)41(54-48 ...... t27-,28-,38-,39-,41-,42+/m0/s1
P235
FHCUMDQMBHQXKK-CDIODLITSA-N
P274
C₄₉H₅₄N₈O₈
P3345
P486
C000604171
P592
CHEMBL3545062
P6366
2778395512
P652
KCU0C7RS7Z